In the BioHarmony Drug Report Database

"Preview" Icon

Basiliximab

Simulect (basiliximab) is an antibody pharmaceutical. Basiliximab was first approved as Simulect on 1998-05-12. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target interleukin-2 receptor subunit alpha.

 

Trade Name

 

Simulect
 

Common Name

 

basiliximab
 

ChEMBL ID

 

CHEMBL1201439
 

Indication

 

graft rejection, kidney transplantation
 

Drug Class

 

Monoclonal antibodies: chimeric, immunomodulating

Image (chem structure or protein)

Basiliximab structure rendering